COCP
Cocrystal Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.95
−7.20%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +21.3%
- EBIT
- +20.5%
- EPS
- +35.5%
- Free cash flow
- +39.1%
- Operating cash flow
- +39.1%
Forward estimates
Based on analyst estimates
- Revenue
- +27.3%
- EBITDA
- +39.1%
- EPS
- +45.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- +51.3%
- EBIT
- +49.6%
- Net income
- +49.5%
- EPS
- +54.7%
- Free cash flow
- +50.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026